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Despite the role of pigs as a source of new Influenza A Virus viruses (IAV) potentially
capable of initiating human pandemics, immune responses to swine influenza virus
(SwIV) in pigs are not fully understood. Several SwIV epitopes presented by swine MHC
(SLA) class I have been identified using different approaches either in outbred pigs or
in Babraham large white inbred pigs, which are 85% identical by genome wide SNP
analysis. On the other hand, some class II SLA epitopes were recently described in
outbred pigs. In this work, Babraham large white inbred pigs were selected to identify
SLA II epitopes from SwIV H1N1. PBMCs were screened for recognition of overlapping
peptides covering the NP andM1 proteins from heterologous IAV H1N1 in IFNγ ELISPOT.
A novel SLA class II restricted epitope was identified in NP from swine H1N1. This
conserved novel epitope could be the base for further vaccine approaches against H1N1
in pigs.
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INTRODUCTION
Swine Influenza is an important respiratory pig disease caused by Influenza AVirus (IAV) (1) which
represents a significant problem to farming but also carries very substantial risks to human health.
Domestic pigs cover an important role in the ecosystem of IAV; it is believed that they may serve
as “mixing vessels” for the generation of novel reassortant influenza A virus potentially capable of
initiating human pandemics (2, 3). Controlling the virus in pig populations is of great importance
not only for implementing and/or improving control and surveillance programs on farms but also
for preventing zoonotic infections. Thus, increasing basic knowledge of immune responses of pigs
to IAV as a basis for developing novel and improved vaccines is of great importance.
Selecting the optimal antigen is a cornerstone in rational vaccine design and depending on the
desired response, proper B or T cell epitopes should be carefully selected. Besides the antibody
response, the T cell response is increasingly gaining more attention in the research of influenza
vaccines due to its importance in protection and its ability to provide a wider breath of protection
by targeting conserved domains (4). The T cell response against influenza is not fully understood
in pigs (5) and even less is known about IAV T cells epitopes recognized by Swine Leucocytes
Antigens (Mayor Histocompatibility Complex of pigs). T cells are considered actively involved
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both in clearance of the primary infection and in the control of
heterologous reinfection of IAV (6). Specific CD4+ and CD8+
T cells are produced locally and systemically in pigs after IAV
infection and they show a multifunction profile, cross-reactivity
and memory similar to viral infections in humans (6, 7).
Reverse vaccinology is not fully developed and accurate for
pigs due to the insufficient data on SLA properties on which
to train and/or test algorithm for prediction of T cell epitopes.
Nevertheless, panmethods have been successfully used to identify
SLA epitopes of both classes (8, 9); these methods can predict
T cell epitopes that bind to MHC for which experimental data
are limited or not available. Therefore, empirical strategies are
still crucial to generate the basic knowledge to generate novel pig
specific prediction methods.
This study aimed to identify novel SLA-II epitopes of IAV
in pigs by means of empirical methods. The Babraham is a
large white inbred pig lineage that is 85% identical by genome
wide SNP analysis (10). The matching of MHC class I and
II alleles between individual animals makes them instrumental
for immunological studies. Babraham’s pigs were immunized
in this study following the concept that inactivated vaccines
are generally designed to present and promote presentation of
extracellular antigens. Thus, those type of antigens should be
preferentially processed toward and presented by class II SLAs.
It has been shown in humans that CD4+ T cell responses
focused mainly on NP and M1 proteins of IAV and that class
II HLA epitopes are most commonly found on internal proteins
(11, 12). For this reason, the specificity of the recall response
produced by overlapping peptides covering the NP and M1
protein from heterologous IAV was tested using PBMC from
immune Babraham’s pigs and an IFNγ ELISPOT assay. In this
way, we were able to identify two new SLA-II restricted epitopes
in a structural protein that was conserved between IAV and
could represent a potential epitope to induce protective responses
against several IAV subtypes.
MATERIALS AND METHODS
Animals
Babraham’s pigs were housed at the Greenfield farm (Compton)
belonging to The Pirbright Institute. Those are inbred large
white pigs syngeneic at the MHC loci. Animals wereMycoplasma
Hyopneumoniae and Porcine Reproductive and Respiratory
Syndrome Virus free. They were vaccinated against Glässer
disease (MSD Animal Health), Erysipelas (Porcillis Ery Injection,
MSD Animal Health), Parvo Virus (Suvaxyn Parvo/E Injection,
Zoetis) and received treatment for Mites and Parasites with
Panomec Injection (Merial). Cohort 1: animals were 25–30 weeks
old and around 39–50Kg of weight; they were labeled B557,
B558, B563, B564, B568, and B570. Cohort 2: animals were 8–
9 weeks old and around 5.5–9.5 Kg of weight; they were labeled
CTRL, 1 and 2. Cohort 3: animals were 2–3 years old and around
173–192Kg of weight; they were labeled B625 and B650. All
studies were carried out under UK Home Office License number
70/7505 and approved by the ethical review processes at The
Pirbright Institute.
Immunizing Antigens
Three type of antigens were selected: SpH1N1, Gripovac3
and S-Flu. The strain A/Swine/Spain/SF11131/2007 (SpH1N1)
belonged to the swine lineage of IAV and in particular to the
European “Avian-like” (13). This was propagated on Madin
Darby Canine Kidney cells (MDCK) as described previously
(13) and inactivated by UV radiations. Inactivation of the virus
was confirmed as absence of formation of any cytopathic effect
after 7 days incubation in a MDCKs monolayer. Integrity of
the viral proteins was indirectly confirmed as consistence of
HemagglutinationUnits (HAU) before and after UV inactivation.
Hemagglutination test was performed as described elsewhere
(WHO). One dose of the immunization antigen SpH1N1 was
prepared by mixing the volume corresponding to 1–3.5 ×
107 TCID50 of the inactivated viral solution with 1ml of
the adjuvant Montanide ISA 206 VG (Seppic). The second
immunizing antigen solution was Gripovac3 (IDTbiologika)
which is constituted by whole inactivated IAVs formulated
with adjuvant. The vaccine contained Europeans strains of
the swine lineage of H3N2, H1N1, and H1N2 subtypes. The
third immunizing antigen was a recombinant live IAV (S-Flu)
constituted by an H5 Hemagglutinin and the rest of proteins
from the human IAV A/PR/8/34. This virus was generated and
attenuated by suppression of HA signal sequence by Dr. Alan
Townsend (University of Oxford, UK) as described in (14). One
dose of S-Flu was containing 6× 107 TCID50.
Pig Immunization and Sampling
The cohorts of pigs selected for the study were immunized with
three different strategies implying two dose of the IAV antigens
administered within a 28 days interval (Table 1). The inactivated
antigens were administered intramuscularly in the front shoulder
of the animals. The live antigens S-Flu was administered in
the nasal cavities using a mucous administration device (Wolfe
Tory Medical). Blood was collected in heparinised tubes by
anterior vena cava venepuncture at 0, 7, 14, and or 21 days post
boost (dpb). Peripheral Blood Mononuclear Cells (PBMCs) were
obtained by density gradient centrifugation of blood, 1,200xg for
30min over Histopaque 1.083 g/ml (Sigma). RBC were lysed
by 5min incubation on ice with Ammonium Cloride buffer
(Ammonium Cloride 155mM, Potassium Bicarbonate 10mM,
EDTA disodium salt 0.1mM) and then washed several time with
PBS. PBMCs samples were stored in liquid nitrogen until use.
Blood was also collected at the same time points for sera recovery.
Finally, animals from herd 1 and 2 were culled at 28 days post
boost (dpb), wheras animals from herd 3 were culled at 14 dpb.
Culture Medium
Culture medium was RPMI-1640 medium with glutamax-
I and 25mM hepes (Life technologies) –emented with
penicillin/streptomycin (Life technologies), and 10% heat-
inactivated pig serum (Life technologies) or fetal calf
serum (Gemini).
Peptides
Pools 1–3 represented the entire NP (GenBank: AFG72805.1)
and M1 (GenBank: AFG72802.1) protein sequences of human
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TABLE 1 | Babraham’s pigs immunization plan.
Immunization Animals 1st dose 2nd dose
Antigen Route Antigen Route
Strategy 1 Cohort 1
B557, B563, B568 SpH1N1 IM SpH1N1 IM
B558, B564, B570 Gripovac3 IM Gripovac3 IM
Strategy 2 Cohort 2
1, 2 SpH1N1 IM SpH1N1 IM
CTRL None None None None
Strategy 3 Cohort 3
B625, B650 SpH1N1 IM S-Flu IN
Two dose of the IAV were administered within a 28 days interval.
IAV strain A/Panama/2007/1999 (H3N2) fused with the amino
acid sequence GGGPGGG. Pool MSP represented the Malaria
Merozoite Surface Protein-1 was used as irrelevant peptide
pool. Pools 1–3 and MSP were constituted by 80 peptides
(numbered 1–80) with length between 17 and 20 amino acids
and overlapping 10 amino acids. Pools A-D were pools of
6–8 peptides from pool 2. The amino acid identity of NP
and M1 proteins between A/Panama/2007/1999 (H3N2) and
SpH1N1 was 90 and 92% respectively; thus they are different
enough to be considered heterologous (<97% sequence identity).
Peptides were synthesized by the laboratory of proteomics
& protein chemistry, Department of experimental & health
sciences of the Pompeu Fabra University (Barcelona, Spain).
All peptides were resuspended in DMSO and diluted in
culture media to reach the desired concentration and stored
at−80◦C until use.
Antigens Testing by ex vivo Tissues
Stimulation
MDCK supernatants corresponded to the vehicle of SpH1N1 and
it was used to determinate the background immune response
produced as consequence of immunization with impure virus
preparation. This antigen was obtained from mock infected
MDCK cells by the same method used to propagate SpH1N1.
Culture media was used to determinate background of the
assays (Media). These and other antigens were diluted in culture
media and when required DMSO. Where specified, DMSO was
added to the stimulus diluted 500-fold to resemble the amount
contained in peptide suspension. PBMCs were stimulated with
the following amount of antigens per 5 × 105 cells: 105 TCID50
of SpH1N1, MDCK sup was diluted like virus, 2 × 105 TCID50
of S-Flu, 1 µg of pools 1–3 and MSP and 0.2 µg of pools A-D
or individual peptides. The restriction of the recalled immune
responses was tested as previously described by (15). Anti SLA-I
and SLA-II antibodies or isotype control antibodies were added
to the ex-vivo recall stimulation of PBMCs as indicated in
Table 3. The produced immune response was then quantified by
IFNγ ELISPOT.
TABLE 2 | Peptides representing the sequences of 43 and 44.
Name Sequence Name Sequence
43a NQQRASAGQISVQPTFSVQR 43m ISVQPTFSVQRNL
43b RASAGQISVQPTFSVQR 43n QISVQPTFSVQRN
43c AGQISVQPTFSVQR 43o ISVQPTFSVQRN
43d QISVQPTFSVQR 44a SVQPTFSVQ
43e SVQPTFSVQR 44b SVQPTFSVQRNL
43f VQPTFSVQR 44c SVQPTFSVQRNLPF
43g ISVQPTFSVQR 44d SVQPTFSVQRNLPFEKS
43h QISVQPTFSVQRNLPF 44e SVQPTFSVQRNLPFEKSTVM
43i ISVQPTFSVQRNLPF 44g SVQPTFSVQRNLP
43j QISVQPTFSVQRNLP Sp44 SVQPTFSVQRNLPFERATIM
43k ISVQPTFSVQRNLP Irrelevant NIKNESKYSNTFINNAYNMS
43l QISVQPTFSVQRNL
The underline text represents the overlapping region of the 2 peptides.
IFNγ ELISPOT
Enzyme-linked immunosorbent spot (ELISPOT) plates were
prepared with the capture antibody mouse anti-pig IFN-γ (Clone
P2G10) (Becton Dickinson) as previously described (16). PBMCs
were plated at 5 × 105 cells per well and stimulated with
antigens as indicated above. Pokeweed mitogen (PWM) 1µg/ml
or Concanavalin A (ConA) 10µg/ml (Sigma) were used to
stimulate 105 PBMC as positive controls of the assay. Plates
were cultured overnight at 37◦C and 5% CO2. Spots were
revealed by using a biotinylated mouse anti-pig IFNγ (Clone
PTC11) (Becton Dickinson) antibody as previously described
(16). Finally, dark blue-colored immunospots were counted
using the AID ELISPOT reader (AID Autoimmun Diagnostika).
Stimulation Index (SI) was calculated as ratio between ISC values
of peptides and background (Media).
Prediction of SLA-II Epitopes
The NetMHCpan 3.2 (17) pan algorithm was used to predict
SLA-II epitopes of the NP of A/Panama/2007/1999 (GenBank:
AFG72805.1). The Babraham’s pigs SLA-II alleles were used as
previously described: SLA-DRB1∗05:01 (IPD-MHC: SLA06022),
SLA-DQA∗01:03 (IPD-MHC: SLA05927) and SLA-DQB1∗08:01
(IPD-MHC: SLA05978) (18); their amino acid sequences were set
up for a customized prediction.
Conservation Analysis of Epitopes in IAV
Non identical and full length sequences of the NP protein of
IAV isolated in swine (n = 2,721), human (n = 3,482) and
avian (n = 5,640) were retrieved from the Influenza Research
Database (19) (through the web site at http://www.fludb.org) (as
of January 13th, 2020). Sequences were aligned with MAFFT (20)
version 7 (https://mafft.cbrc.jp/alignment/server/large.html); the
alignment was inspected and curated by using Jalview (21)
version 2.11.0. The region spanning the identified epitope
sequences were used to generate a logo byWeblogo3 (22) version
3.7.4 (http://weblogo.threeplusone.com/).
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TABLE 3 | Immunological reagents.
Clone Subtype Fluorophore Brand Amount
MHC BLOCKING 5 × 105 cells
1◦Antibodies
SLA-I 74-11-10 IgG2a – Kingfisher and in house 15 µg
SLA-II MSA-3 IgG2b – Kingfisher and in house 15 µg
Isotype controls
W6/32 IgG2a – In house NA
Data Analysis
Data were transformed and graphed with Prism v5.01
(GraphPad). Descriptive statistics including distribution
images of results and tables were performed with SAS system
V.9.1.3 (SAS institute). Non-parametric statistics analysis
was performed with Wilcoxon test implemented from SAS
software. Individual pigs were used as experimental unit. The
significance level (p) was set at <0.05 with tendencies reported
when p < 0.1.
RESULTS
Ex-vivo IFNγ Recall Responses in
Babraham’s Pigs
Babraham’s pigs (Cohorts 1–3) were sequentially and differently
administered with attenuated live and/or inactivated IAV
antigens; the immunization strategy was set up and tested
empirically with the aim of improving the ex vivo IFNγ secretion
response against IAV. The tissues collected from these pigs were
then tested ex-vivo to evaluate the immunization performances
and also to identify and characterize T cell epitopes of IAV.
The immunizations strategies primed an IFNγ secreting response
against the live (S-Flu) or inactive (SpH1N1) whole virus when
tested by ELISPOT (Figures 1A–D). Viruses used to immunize
the pigs were genetically divergent (13) but despite this, they were
able to produce a cross-reacting IFNγ response. In particular, S-
Flu belonged to a completely different lineage of IAV compared to
SpH1N1 or Gripovac3 antigens; however, it was able to recall ex-
vivo an IFNγ response on PBMC collected from pigs immunized
with SpH1N1 (Cohort 2) (Figure 1B).
Identification of an Antigenic Regions in
the M1 and NP Proteins of IAV
The strain A/Panama/2007/1999 (H3N2) is an IAV belonging
to a different subtype and lineage compared to the antigens
used for the immunization of pigs. In particular, its M1
and NP proteins shared between 92.06–95.63% and 89.76–
91.97% of the amino acid sequences, respectively, with them.
To identify the antigenic regions able to produce a cross
reacting IFNγ response, a collection of overlapping peptides
representing the two proteins of A/Panama/2007/1999 were
tested ex vivo by ELISPOT. All peptides were initially tested in
pools (pools 1–3) and subsequently dissected into smaller subsets
up to identify those individual peptides inducing a statistically
significant IFNγ secretion response. Pool 1 and 2 represented
the NP protein whereas pool 3 represented the M protein of
IAV. The assay was initially performed by using the PBMCs
purified from Babraham’s pigs immunized with the heterologous
antigens SpH1N1 and Gripovac3 (Cohort 1 and Cohort 2). The
immunodominant response was obtained by pool 2 being the
other pools not responding (Figures 1A,B,D). Further analysis
of peptides included in pool 2 identified peptide 43 and 44 as
immunodominant (Figures 1B,D).
To identify the shortest amino acid sequence inducing an
IFNγ secretion response, a new set of peptides with sequential
deletion of the end terminals regions was designed from the
peptides 43 and 44 sequences (Table 2). This set of peptides
was then tested by ELISPOT using PBMCs from Babraham’s
pigs immunized with the heterologous antigens SpH1N1 and
S-Flu (Cohort 3). The shortest identified immunogenic regions
(Figures 1C,E) were represented by peptides 43d and 44c which
were then further dissected with a new set of peptides designed
with the same strategy adopted before (Table 2). Moreover,
IFNγ secretion responses induced by the region spanning
the entire sequence of peptide 43d and 44c was also tested
(Figure 1F). Unfortunately, the potency to carry out a statistical
analysis was extremely low. Thus, it was almost impossible
to find significant differences among peptides. Peptide 43g
and 44g were the shortest immunogenic regions identified in
this study. Notably, the removal of I at the left terminal of
peptide 43g and NLP in 44g was fundament to maintain the
immunogenic properties of each peptide. The effects of the
right and left terminal end amino acids of peptides 43g and
44g were not further characterized. Moreover, the following
effects have been observed: Peptide 43k and 43i fulfilled the
hypothesis that the sum of 2 epitopes (44g and 43g) increased
responses compared to those observed by stimulation with each
one alone. Peptide 43j showed that simultaneous addition of
Q and P amino acids enhance IFNγ response of peptide 43k.
Finally, peptide 43h suggested that F partially suppress responses
of 43J.
Peptide 43g and 44g corresponded, respectively, to
regions NP406−416 (ISVQPTFSVQR) and NP407−419
(SVQPTFSVQRNLP) of A/Panama/2007/1999. Conservation
of these regions in the IAV used as immunization antigens in
this study was inspected. Region NP406−419 was mutated in
H3N2 virus contained in Gripovac3 (I406V) and in the S-Flu
(V408I) whereas it was completely conserved in the H1N1 and
H1N2 strains of Gripovac3 and also in SpH1N1. Therefore, the
Babraham’s pigs were immunized at least once with an antigen
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FIGURE 1 | Empirical identification of T cells epitopes. A collection of peptides spanning the NP and M1 proteins of A/Panama/2007/1999 was used to stimulate ex
vivo the PBMCs collected from Babraham’s pigs. These were previously immunized using either (A) strategy 1 (i) SpH1N1 and (ii) Gripovac3 immunized pigs, (B)
strategy 2 or (C,E,F) strategy 3. The recalled immune response was quantified by an IFNγ ELISPOT and calculated as number of interferon Gamma Secreting cells
(ISC) per 106 PBMCs (A,B,F). The results obtained throughout the tests and cohorts were transformed as Stimulation Index (SI) and summarized in (D,E); each dot
represents the average value from a single assessment in a pig. The peptides were tested as pools (pools 1–3, pools A–D) and individually (39–45, 43a−44e,
44g−43h). The letters on the top of the graph in (E) represent the amino acids sequentially deleted from peptide 43a NQQRASAGQISVQPTFSVQR or 44e
SVQPTFSVQRNLPFEKSTVM. In contrast the letter on the top of the graph in (F) represent the amino acid sequentially added from the peptide 43–44 overlapping
region (in bold). The UV-inactived SpH1N1 and live S-Flu (H5) IAVs were used to recall a specific immune response in the immunized pigs. The MSP pool, the
irrelevant peptide, the media either supplemented or not with DMSO were used to evaluate the non-specific response of the testing system. The MDCK sup was used
to evaluate the non-specific immune response against the whole virus and in particular the derived from the replication system adopted. Finally, the PWM either
supplemented or not with DMSO and the ConA were used to check the responsiveness of the PBMCs used in the assay. Statistically significant differences in (A–C)
are indicated by asterisk (Wilcoxon signed-rank test; p < 0.05). Figures are representative of three independent experiments.
containing the same sequence of the IAV epitopes identified in
this study.
Identification of the SLA Class Restriction
The SLA class restriction of NP406−416 andNP407−419 (contained,
respectively, in peptides 43 and 44) was inferred by testing their
immunogenicity in presence of either an anti SLA-I or SLA-II
antibody. PBMCs from Babraham’s pigs immunized with IAV
were stimulated ex-vivo with the peptides in presence of either
of the anti SLA antibodies which blocked the responses mediated
by those receptors; the produced immune response was then
quantified by an IFNγ ELISPOT. Responses induced by the tested
antigens was inhibited by the anti SLA-II antibody with much
greater magnitude compared to anti SLA-I antibody (Figure 2).
In particular, the first inhibited 84 and 86% of peptides 43 and 44
recall responses, respectively; in contrast, <25% of the responses
were blocked by the anti SLA-I antibodies.
The IEDB database was then inquired to investigate whether
other MHC-II epitopes were described falling in the region
NP406−419, regardless the species associated. For this purpose, a
search for similar linear MHC-II restricted (blast 70%) epitopes
was set up. The database contained 17 sequences of MHC-II
restricted epitopes related to the NP407−419 of IAV deposited
up to 2019 (Figure 3); notably, the human MHC-II HLA-DRB
were the most related alleles, when this specific information
was available.
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FIGURE 2 | SLA class restriction of the identified immunogenic regions. The peptides 43 and 44 were used to recall ex-vivo an immune response in PBMC collected
from pigs immunized with IAV (cohort 3) in presence of SLA-II and SLA-I specific antibodies. The response was then quantified by IFNγ ELISPOT and calculated as
ISC/106 PBMCs. The irrelevant peptide was used to evaluate the specificity of the peptide induced response. The isotype control antibodies were used to check the
specificity of the restriction of the anti SLA antibodies. (A) The response of each tested pigs was represented as mean with sd; the asterisks indicate a statistically
significant difference (Wilcoxon signed-rank test; n = 3; p < 0.05). (B) Percentage of the ISC/106 PBMCs recalled in presence of anti SLA-antibodies compared to
their absence. The asterisk indicates a statistically significant difference (Wilcoxon signed-rank test; inter assay n = 4; p < 0.05).
The relationship of NP406−416 and NP407−419 with the
Babraham’s pigs SLA-II alleles was tentatively inferred by in-
silico prediction. As there are no open available algorithm of
prediction designed specifically for pigs a pan algorithm was
used for such purpose The Babraham’s pigs SLA-II alleles (DRB1
and DQ) and the NP (A/Panama/2007/1999) sequences were set
up in NetMHCpan 3.2. The resulting peptide sequences were
ranked depending on their predicted affinities and then those
sharing part of their sequence with NP406−416 and NP407−419
were retrieved. Notably, NP412−420 FSVQRNLPF and NP406−414
ISVQPTFSV were ranking, respectively, among the top 2%
(strong binders) and 10% (weak binders) of the 9mer predicted
peptides for the SLA-DRB1. In contrast, no similar epitope was
found for the SLA-DQ.
The SLA-II allele restriction of the region NP406−419 was
tentatively tested as described above but in presence of antibodies
specific for the alleles DR and DQ to give support to the
above predictions. The antibody specific for the SLA-II DR allele
decreased up to a maximum of 80% the responses of peptides
43i and 43j (Figure 1 SI). The assay had low power as it was
performed just two times in a single pig and thus it deserved
further studies.
Conservation of NP406−416 and NP407−419
Among IAV
Conservation of the identified epitopes was inspected in the
IAV isolated from the three major host species (swine, human
and avian specie). For this purpose, a collection of non-
redundant full NP sequences of IAV was retrieved from a
public domain database and aligned; the generated database
was therefore meant to contain unique variants of IAV. Then
the variability at the region NP407−419 were presented as logo
in Figure 4. SwIV showed a high conservation of the entire
sequence; in particular, NP417 (98.09%) and NP406 (98.97%)
were the least conserved positions, whereas the rest of the
sequence was conserved in more than 99% of SwIV strains
(Table 1 SI).
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FIGURE 3 | Alignment of the MHC-II epitopes similar to NP406−419 described.
The red square indicates the region shared by most of the epitopes. The code
on the left represent the IEDB reference.
Human IAV showed an inconsistent conservation throughout
the NP407−419 sequence. Position NP406 was conserved in just
59.82% of the inspected strains whereas 38.71% of the rest of
them showed the mutation I406T (Table 1 SI). Notably, 98.04%
(n = 1,327) of the strains bearing the mutation I406T were
belonging to the H3N2 subtype (Table 2 SI); this was not a
bias due to an over representation of the H3N2 subtype in the
database as they constituted the 48.7% of the strains, whereas the
H1N1 constituted the 43.5%. The number of strains containing
Isoleucine or Threonine amino acids at position NP406 were
distributed throughout the last 51 years (since the introduction
of H3N2 IAV in humans) depending on their isolation time.
Figure 5 showed that I406T mutation started to be detected
since the 2000 and its presence increased dramatically up to
2017. Other least conserved positions were, respectively, NP408
(91.67%), NP411 (96.41%) and NP418 (98.48%) whereas the rest
were conserved in more than 99% of the inspected human IAV
strains (Table 1 SI).
The avian IAV also showed the lowest conserved
position at NP406, however, unlike human IAV, Isoleucine
FIGURE 4 | Conservation of NP406−419, ISVQPTFSVQRNLP. The logo was
generated using unique NP sequences of IAV isolated from (A) swine (B)
human or (C) avian species. Letters represent the amino acid code and their
height is proportional with the frequency.
was found in a higher proportion of strains (91.79%).
This position showed a high preference for the mutation
I406V (8.10%). Positions NP417 and NP408 were conserved,
respectively, in 94.38 and 95.20%, whereas, the rest of
position was conserved in more than 99% of avian IAV
(Table 1 SI).
Based on the conservation findings, the cross-reactive
propriety of the identified region NP406−419 was tentatively
tested in a completely different experiment. PBMCs samples
were retrieved from a previous study conducted in Babraham’s
pigs in which they were immunized with a non-adjuvated whole
A(H1N1)pdm/09 influenza vaccines licensed for humans (16).
This NP segment of this virus derived from the “classical”
SwIV which is a different lineage compared to the immunizing
antigens used above. Results showed that peptides 43i and 43j
were able to recall an IFNγ secretion responses in one of
the immunized pigs whereas the rest and the mock-vaccinated
pigs were not responding (Figure 2 SI). However, the assay had
low power as it was repeated two times and thus it deserved
further studies.
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FIGURE 5 | Dynamic of the I406T amino acid mutation in sequenced H3N2 IAV variants since their introduction in humans. Dotted line represents the number of
strains having I406 whereas the continuous line represents the number of strains having T406 in their NP protein.
DISCUSSION
The CD4+ T cell response is considered of great importance in
immune response against IAV; it provides help to CD8+ T cell
and B cell responses but it also directly controls virus spread by
means of cytotoxic effects on infected cells [Reviewed in (23)].
Novel strategies of rational design of IAV vaccines are therefore
considering to modulate T cell responses including not only CD8
but also the CD4 subsets (4).
In swine, few SLA-II epitopes of IAV have been identified,
as compared to HLA epitopes. In the present study, SLA-II
epitopes of IAV were identified in pigs by using an empirical
approach. Babraham’s pigs were used as model to identify T
cells epitopes because their syngeneic MHC loci which aids
identification of SLA restriction of the identified epitopes.
Previous studies demonstrated that immunization strategies
based on the administration of whole inactive virus (WIV)
formulated with adjuvant in pigs were able to produce an IFNγ or
proliferative cell mediated response in peripheral blood involving
T helper subsets (8, 16, 24). Moreover, the generated immunity
was also able to respond to heterologous IAV strains (24).
Similar results were obtained in this study by boost
immunization of Babraham’s pigs with live and/or inactivated
whole IAV antigens; in particular, the latter was constituted by
an in-house UV-inactivated IAV formulated with adjuvant or
a commercially available vaccine which was licensed by that
time in pigs. The adopted immunization strategies produced
a specific IFNγ immune response in the Babraham’s pigs; this
was recalled ex vivo by stimulating PBMC with homologous and
even heterologous IAV antigens and it was detected by means
of an IFNγ ELISPOT assay. This study is therefore supporting
previous finding that influenza vaccines for pigs based on
WIV and formulated with adjuvant are able to generate T cell
responses with IFNγ secreting effector functions; moreover,
it supports the generation of T cell responses with cross
reactivity against viruses of different linages For this purpose,
a collection of peptides spanning the entire length of the NP
and M1 proteins was tested ex-vivo by using an IFNγ ELISPOT
assay on PBMC harvested from Babraham’s pigs previously
immunized with IAV. The adopted immunization and screening
strategies permitted to successfully identify two overlapping
immunogenic regions: NP406−416 (ISVQPTFSVQR) and
NP407−419 (SVQPTFSVQRNLP). Despite sharing most of their
sequences, they are considered different epitopes because the
non-overlapping positions (NP406 and NP417−419) were critical
to maintain their respective immunogenic proprieties. NP406−416
(ISVQPTFSVQR) and NP407−419 (SVQPTFSVQRNLP are the
shortest epitopes tested in this study, the effect of the removal of
the amino acid at the right terminal of NP406−416 or both end
terminals of NP407−419 were not tested. The MHC restriction
of the identified regions was inferred by blocking IFNγ recall
responses with class specific antibodies, a strategy previously
adopted in pigs by other authors (15). Peptides containing the
identified regions showed specificity for the SLA-II; therefore, no
SLA-I epitope was identified in this study.
A previous study demonstrated that immunization with
inactive IAV antigens is able to produce a Cytotoxic T
lymphocytes response against the whole virus in Babraham’s
pigs, although this was detected as proliferative response (16);
moreover, SLA-1 of the same pig lineage were identified in
the NP protein of IAV by means of a strategy involving long-
term in vitro pig T-cell culture and cloning (25). Therefore, the
missed identification of SLA-I epitopes might have been due to
differences in the immunization and/or screening strategy.
The IDEB database contained just three M1 and one NP
related epitopes restricted to the SLA-II. These were discovered
by previous authors using in silico prediction followed by ex-
vivo IFNγ ELISPOT testing (8). In the present study, no SLA-II
epitope producing an IFNγ recall response was identified in the
M1 protein whereas the epitopes found in the NP were located
in a different region compared to the one previously published
(NP253−277). These differences might have been due to the allele
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diversity between the cohorts of pigs of the two studies, the
SLA low resolution alleles found by the authors were different
compared to Babraham’s pigs.
Despite the absence of similar epitopes in pigs, several
human MHC-II epitopes were previously identified by other
authors. Notably, most of those were restricted to HLA-DRB1
alleles and raised the question whether this affinity might
have been conserved in pigs as well. The pan algorithm
NetMHC II 3.2 was used to predict epitopes of the NP of
A/Panama/2007/1999 associated to the Babraham’s pig SLA-II
allele. Notably, two 9mer epitopes were predicted for the SLA-
DRB1, NP412−420 FSVQRNLPF and NP406−414 ISVQPTFSV;
these epitopes were partially contained in the sequences of
epitopes NP406−416 and NP407−419 identified in this study. A
proof of concept test conducted with low power showed that
the immunogenic response produced by peptides containing the
region NP406−416 was not restricted to the DQ allele but instead
by the DRB allele. Therefore, these results support the idea that
those epitopes might be associated to the SLA-DRB1 allele in
Babraham’s pigs, however, further study are required to validate
the in silico prediction.
Different functionally polarized subpopulations have been
established in studies with murine and human CD4+ T cells
and just a part of these were elucidated in pigs (26). This is a
mayor limitation in the SLA-II epitope discovery strategies in pigs
whereby cytokines are biomarker of cells responsiveness. In the
present study, IFNγ was used as functional marker to quantify
the recall response to the overlapping IAV peptide collections
in peripheral blood. This cytokine is generally associated in pigs
to the Th1 subset of the CD4+ T cells (26). Single and double
producer of IFNγ and TNFα dominated the response of CD4+
T cells in blood and other tissues during an IAV infection in
pigs and thus they were suggested to be important in its control
(6). Therefore, the immunogenicity of NP406−416 and NP407−419
during infection and their involvement in protection deserve
further studies. The encounter SLA-II epitopes might be also
helpful under other effector functions. The phenotype of CD4+
T cells depends on the “cytokine milieu” (27) and thus this might
be rationally modulated to a specific phenotype involved in other
T helper functions.
Sequence conservation of epitopes is an important aspect to
take into account during the rational design of an IAV vaccine.
The use of conserved epitopes could contribute to the breadth of
protection conferred by the vaccine. The SLA-II T cell epitopes
identified in this study were hailing from the human IAV strain
A/Panama/2007/1999 (H3N2) and despite this, they showed to
be able to induce a cross reacting response in pigs immunized
with IAV of completely different lineages. This fact was due to
the complete conservation of their amino acid sequences among
the antigens used in this study. NP and M1 proteins are codified
by the internal cassette of genes of IAV which is by far more
conserved compared to the HA and NA coding genes. Notably,
the internal cassette of the European swine lineages of the H3N2
andH1N2 subtypes is evenmore conserved because it was shared
by the H1N1 avian like lineage through reassortment events.
The analysis of swine IAV showed an impressive conservation
of the NP406−419 sequence which suggests this region might
be an optimal candidate for development of a broad reacting
vaccine for pigs. Nevertheless, conservation of the sequence in
other mayor species is also an important factor to take into
account for the design of a broad protecting vaccine. IAV has
the ability to cross the specie barrier whereas pigs have the
ability to act as a “mixing vessel” and also to perpetrate other
species lineages. Human and avian species are the other two
major known host of IAV; these might act as reservoir of
novel variants that might escape from the pig immune system
recognition of NP406−419. Conservation analysis showed that
this sequence was less conserved in human and avian IAV; in
particular, the site NP406 showed the lowest conservation in
both lineages, especially in the human. Notably, results showed
that the mutation I406T is highly frequent in human IAV
lineage and it was particularly associated with H3N2 strains
circulating since the ‘00s. During the same period a transition to
a novel antigenic cluster [A/Fujian/411/2002 (FU02)] linked to
a persistent reassortment event was observed (28). Considering
the common ancestor between the avian IAV and other species
lineages it was not surprising to find the conserved amino acid
Isoleucine at the position NP406; however, results showed that
the divergent evolution of IAV in human hosts is apparently
changing permanently its composition. NP406 was a critical
position to maintain the immunogenic properties of the epitope
NP406−416 and actually its removal disrupted the capacity of the
T cell epitope to recall an IFNγ response in the immunized pigs.
The effects of mutations at NP406 on the immune proprieties
of the T cell epitope are unknown; because of the variability
and evolution of the IAV, this position deserve further studies to
evaluate its antigenic tolerance.
The overall high conservation of NP406−419 is probably
due to its functional importance in the NP protein. The
region is localized into a flexible tail-loop (residues 402–428)
which mediate the NP-NP oligomerization (29). In this region,
positions like the R416 can be found which is critical for
the functionality of the protein (29); therefore, this region
is expected to be less permissive to mutations. Thus, region
NP406−419 can be considered an optimal candidate for vaccines
research due to the presence of T cells epitopes and its
high conservation.
Considering the high conservation in the epitope, a
proof of concept test was conducted with low power to
evaluate the cross reactivity of the identified immunogenic
region NP406−416. Results showed that this region showed
to be immunogenic in pigs even in a different immunity
scenario involving the A(H1N1) pdm/09 influenza
vaccines and thus support its validity as candidate for
further studies.
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